|
1
|
Jemal A, Siegel R, Xu and Wrad E: Cancer
statistics, 2010. Ca Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar
|
|
2
|
Cohen HT and McGoven FJ: Renal-cell
carcinoma. N Engl J Med. 353:2477–2490. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Nagase H and Woessner JF Jr: Matrix
metalloproteinases. J Biol Chem. 274:21491–21494. 1999. View Article : Google Scholar
|
|
4
|
Egeblad M and Werb Z: New functions for
the matrix metalloproteinases in cancer progression. Nat Rev
Cancer. 2:161–174. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Björklund M and Koivunen E:
Gelatinase-mediated migration and invasion of cancer cell. Biochim
Biophys Acta. 1755:37–69. 2005.PubMed/NCBI
|
|
6
|
Brew K, Dinakarpandian D and Nagase H:
Tissue inhibitors of metalloproteinases: evolution, structure and
function. Biochem Biophys Acta. 1477:267–283. 2000.PubMed/NCBI
|
|
7
|
Baker AH, Ahonen M and Kähäri VM:
Potential applications of tissue inhibitor of metalloproteinase
(TIMP) overexpression for cancer gene therapy. Adv Exp Med Biol.
465:469–483. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hayakawa T, Yamashita K, Tanzawa K,
Uchijima E and Iwata K: Growth-promoting activity of tissue
inhibitor of metalloproteinase-1 (TIMP-1) for a wide range of
cells. A possible new growth factor in serum. FEBS Lett. 298:29–32.
1992. View Article : Google Scholar
|
|
9
|
Visse R and Nagase H: Matrix
metalloproteinases and tissue inhibitors of metalloproteinases.
Structure, functions and biochemistry. Cir Res. 92:827–839. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Stetler-Stevenson WG: Tissue inhibitors of
metalloproteinases in cell signaling: metalloproteinase independent
biological activities. Sci Signal. 1:re62008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sobin LH and Wittekind CH: International
Union Against Cancer (UICC) TNM classification of malignant tumors.
6th edition. Wiley-Liss; New York, NY: pp. 193–195. 2002
|
|
12
|
Di Carlo A: Matrix metalloproteinase -2
and -9 in the sera and in the urine of human oncocytoma and renal
cell carcinoma. Oncol Rep. 28:1051–1056. 2012.PubMed/NCBI
|
|
13
|
Struckmann K, Mertz K, Steu S, Storz M,
Staller P, Krek W, Schraml P and Moch H: pVHL co-ordinately
regulates CXCR4/CXCL12 and MMP2/MMP9 expression in human clear-cell
renal cell carcinoma. J Pathol. 214:464–471. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kallakury BV, Karikehalli S, Haholu A,
Sheehan CE, Azumi N and Ross JS: Increased expression of matrix
metalloproteinases 2 and 9 and tissue inhibitors of
metalloproteinases 1 and 2 correlate with poor prognostic variables
in renal cell carcinoma. Clin Cancer Res. 7:3113–3119. 2001.
|
|
15
|
Bhuvarahamurthy V, Kristiansen GO,
Johannsen M, Loening SA, Schnorr D, Jung K and Staack A: In situ
gene expression and localization of metalloproteinases MMP1, MMP2,
MMP3, MMP9 and their inhibitors TIMP1 and TIMP2 in human renal cell
carcinoma. Oncol Rep. 15:1379–1384. 2006.PubMed/NCBI
|
|
16
|
Kugler A, Hemmerlein B, Thelen P,
Kallerhoff M, Radzun HJ and Ringert RH: Expression of
metalloproteinase 2 and 9 and their inhibitors in renal cell
carcinoma. J Urol. 160:1914–1918. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kamiya N, Kishimoto T, Suzuki H, Sekita N,
Nagai Y, Oosumi N, Kito H, Tochigi N, Shinbo M, Nemori R, Ichikawa
T, Igarashi T, Ito H and Ishikura H: Increased in situ
gelatinolytic activity in renal cell tumor tissues correlates with
tumor size, grade and vessel invasion. Int J Cancer. 106:480–485.
2003. View Article : Google Scholar
|
|
18
|
Lein M, Jung K, Laube C, Hübner T,
Winkelmann B, Stephan C, Hauptmann S, Rudolph B, Schnorr D and
Loening SA: Matrix-metalloproteinases and their inhibitors in
plasma and tumor tissue of patients with renal cell carcinoma. Int
J Cancer. 85:801–804. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Cannon GM Jr and Getzenberg RH: Urinary
matrix metalloproteinases activity is not significantly altered in
patients with renal cell carcinoma. Urology. 67:848–850. 2006.
View Article : Google Scholar
|
|
20
|
Sherief MH, Low SS, Miura M, Kudo N,
Novick A and Weimbs T: Matrix metalloproteinase activity in urine
of patients with renal cell carcinoma leads to degradation of
extracellular matrix proteins: possible use as a screening assay. J
Urol. 169:1530–1534. 2003. View Article : Google Scholar
|
